β-arrestin-biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 28, 2016, Pages E4107-E4116

  Carr, Richard ^a   Schilling, Justin ^a   Song, Jianliang ^b   Carter, Rhonda L ^b   Du, Yang ^c   Yoo, Sungsoo M ^a   Traynham, Christopher J ^b   Koch, Walter J ^b   Cheung, Joseph Y ^b   Tilley, Douglas G ^b   Benovic, Jeffrey L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arrestin; Carvedilol; GPCR; Heart failure; Pepducin

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ARRESTIN; CALCIUM; CARVEDILOL; ICL 19; INOTROPIC AGENT; ISOPRENALINE; PHOSPHOLAMBAN; SALBUTAMOL; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; ICL1-9 PEPDUCIN; LIPOPEPTIDE; PROPANOLAMINE DERIVATIVE;

ADULT; ANIMAL CELL; ARTICLE; BETA ADRENERGIC STIMULATION; CALCIUM MOBILIZATION; CALCIUM SIGNALING; CARDIAC MUSCLE CELL; CELL SURVIVAL; COMPARATIVE EFFECTIVENESS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; HUMAN; HUMAN CELL; INOTROPISM; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; COMPARATIVE STUDY; DRUG EFFECTS; HEART CONTRACTION; HEART FAILURE; HEK293 CELL LINE; PRECLINICAL STUDY; PRIMARY CELL CULTURE; PROTEIN CONFORMATION; TUMOR CELL LINE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BETA-ARRESTINS; CARBAZOLES; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; HEART FAILURE; HEK293 CELLS; HUMANS; LIPOPEPTIDES; MICE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PRIMARY CELL CULTURE; PROPANOLAMINES; PROTEIN CONFORMATION;

EID: 84978128490     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1606267113     Document Type: Article

References (48)

1. Javed U, Deedwania PC (2009) Beta-adrenergic blockers for chronic heart failure. Cardiol Rev 17(6):287-292.
2. Ramani GV, Uber PA, Mehra MR (2010) Chronic heart failure: Contemporary diagnosis and management. Mayo Clin Proc 85(2):180-195.
3. Wisler JW, et al. (2007) A unique mechanism of beta-blocker action: Carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci USA 104(42):16657-16662.
4. Erickson CE, et al. (2013) The β-blocker nebivolol is a GRK/β-arrestin biased agonist. PLoS One 8(8):e71980.
5. Carr R, 3rd, et al. (2014) Development and characterization of pepducins as Gs-biased allosteric agonists. J Biol Chem 289(52):35668-35684.
6. O'Callaghan K, Kuliopulos A, Covic L (2012) Turning receptors on and off with intracellular pepducins: New insights into G-protein-coupled receptor drug development. J Biol Chem 287(16):12787-12796.
7. Lefkowitz RJ (2007) Seven transmembrane receptors: Something old, something new. Acta Physiol (Oxf) 190(1):9-19.
8. Tran TM, et al. (2004) Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the beta2-adrenergic receptor using phosphoserine-specific antibodies. Mol Pharmacol 65(1):196-206.
9. Vaughan DJ, et al. (2006) Role of the G protein-coupled receptor kinase site serine cluster in beta2-adrenergic receptor internalization, desensitization, and beta-arrestin translocation. J Biol Chem 281(11):7684-7692.
10. Nobles KN, et al. (2011) Distinct phosphorylation sites on the β(2)-adrenergic receptor establish a barcode that encodes differential functions of β-arrestin. Sci Signal 4(185):ra51.
11. Kang DS, Tian X, Benovic JL (2014) Role of β-arrestins and arrestin domain-containing proteins in G protein-coupled receptor trafficking. Curr Opin Cell Biol 27:63-71.
12. Covic L, Misra M, Badar J, Singh C, Kuliopulos A (2002) Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 8(10):1161-1165.
13. Stampfuss JJ, Schrör K, Weber AA (2003) Inhibition of platelet thromboxane receptor function by a thrombin receptor-targeted pepducin. Nat Med 9(12):1447, author reply 1447-1448.
14. Winther M, Gabl M, Welin A, Dahlgren C, Forsman H (2015) A neutrophil inhibitory pepducin derived from FPR1 expected to target FPR1 signaling hijacks the closely related FPR2 instead. FEBS Lett 589(15):1832-1839.
15. Quoyer J, et al. (2013) Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc Natl Acad Sci USA 110(52):E5088-E5097.
16. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69:483-510.
17. Patel PA, Tilley DG, Rockman HA (2008) Beta-arrestin-mediated signaling in the heart. Circ J 72(11):1725-1729.
18. Shenoy SK, et al. (2006) β-arrestin-dependent, G protein-independent ERK1/2 activation by the β2 adrenergic receptor. J Biol Chem 281(2):1261-1273.
19. Noma T, et al. (2007) Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 117(9):2445-2458.
20. Kim IM, et al. (2008) Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci USA 105(38):14555-14560.
21. Luttrell LM (2014) Minireview: More than just a hammer: Ligand "bias" and pharmaceutical discovery. Mol Endocrinol 28(3):281-294.
22. Chidiac P, Hebert TE, Valiquette M, Dennis M, Bouvier M (1994) Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol 45(3):490-499.
23. Samama P, Pei G, Costa T, Cotecchia S, Lefkowitz RJ (1994) Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. Mol Pharmacol 45(3):390-394.
24. Kang Y, et al. (2015) Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser. Nature 523(7562):561-567.
25. Szczepek M, et al. (2014) Crystal structure of a common GPCR-binding interface for G protein and arrestin. Nat Commun 5:4801.
26. Shukla AK, et al. (2014) Visualization of arrestin recruitment by a G-protein-coupled receptor. Nature 512(7513):218-222.
27. Rasmussen SG, et al. (2011) Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477(7366):549-555.
28. Yao X, et al. (2006) Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor. Nat Chem Biol 2(8):417-422.
29. Yao XJ, et al. (2009) The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proc Natl Acad Sci USA 106(23):9501-9506.
30. Burtey A, et al. (2007) The conserved isoleucine-valine-phenylalanine motif couples activation state and endocytic functions of beta-arrestins. Traffic 8(7):914-931.
31. Zhu WZ, et al. (2003) Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II. J Clin Invest 111(5):617-625.
32. Bisognano JD, et al. (2000) Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 32(5):817-830.
33. Engelhardt S, Hein L, Wiesmann F, Lohse MJ (1999) Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96(12):7059-7064.
34. Woo AY, Xiao RP (2012) β-Adrenergic receptor subtype signaling in heart: From bench to bedside. Acta Pharmacol Sin 33(3):335-341.
35. Wei H, et al. (2003) Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100(19):10782-10787.
36. Rajagopal K, et al. (2006) Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci USA 103(44):16284-16289.
37. Violin JD, et al. (2010) Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335(3):572-579.
38. Boerrigter G, et al. (2011) Cardiorenal actions of TRV120027, a novel β-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: A novel therapeutic strategy for acute heart failure. Circ Heart Fail 4(6):770-778.
39. Bristow MR, et al. (1986) Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 59(3):297-309.
40. Bristow MR, et al. (1993) Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J Clin Invest 92(6):2737-2745.
41. Mangmool S, Shukla AK, Rockman HA (2010) beta-Arrestin-dependent activation of Ca(2+)/calmodulin kinase II after beta(1)-adrenergic receptor stimulation. J Cell Biol 189(3):573-587.
42. Sucharov CC, et al. (2006) A beta1-adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal gene induction. Am J Physiol Heart Circ Physiol 291(3):H1299-H1308.
43. Böhm M, et al. (1994) Radioimmunochemical quantification of Gi alpha in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure. J Mol Cell Cardiol 26(2):133-149.
44. Feldman AM, et al. (1988) Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest 82(1):189-197.
45. Zhu WZ, et al. (2001) Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA 98(4):1607-1612.
46. Daunt DA, et al. (1997) Subtype-specific intracellular trafficking of alpha2-adrenergic receptors. Mol Pharmacol 51(5):711-720.
47. Rosenbaum DM, et al. (2007) GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318(5854):1266-1273.
48. Wang J, et al. (2011) Regulation of in vivo cardiac contractility by phospholemman: Role of Na+/Ca2+ exchange. Am J Physiol Heart Circ Physiol 300(3):H859-H868.